---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-078840"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:32:01.181961+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences shareholders approve reverse stock split authorization and elect directors

## Summary
- All five director nominees elected; Yutaka Niihara, MD received 23.2M votes for.
- Approved amendment to authorize reverse stock split at ratio between 1:5 and 1:8 within one year.
- Ratification of Baker Tilly as independent auditor for fiscal 2022 approved with 29.5M votes for.

## SEC filing metadata
- accession: 0001213900-22-078840
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/0001213900-22-078840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/ea169928-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-078840
- JSON: https://secwatch.observer/filing/0001213900-22-078840.json
- Plain text: https://secwatch.observer/filing/0001213900-22-078840.txt

## Key facts
- Shareholder Votes
  Emmaus Life Sciences, Inc. shareholders approved To approve the amendment to our restated certificate of incorporation to authorize a reverse stock split at the 2022-12-08 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2022-12-08
  source text: Proposal 2: Votes For Votes Against Votes Withheld Broker Non-Votes To approve the amendment to our restated certificate of incorporation to authorize our Board of Directors in its discretion to effect a reverse stock split of the outstanding shares of our common stock within one year following the Annual Meeting at a ratio of not less than 1-for-5 nor greater than 1-for-8 28,880,074 679,945 40,068 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/0001213900-22-078840-index.htm
- Shareholder Votes
  Emmaus Life Sciences, Inc. shareholders approved To elect the five nominees named below to our Board of Directors at the 2022-12-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2022-12-08
  source text: Proposal 1: To elect the five nominees named below to our Board of Directors, to serve until the next annual meeting of stockholders and until their successors are elected and qualified or their earlier retirement, resignation or removal: Votes For Votes Withheld Broker Non-Votes Yutaka Niihara, M.D., M.P.H. 23,176,995 400,562 6,022,530 Willis C. Lee 23,194,026 383,531 6,022,530 Seah Lim, M.D., Ph.D. 23,233,528 344,029 6,022,530 Wei Peu Derek Zen 23,229,478 348,079 6,022,530 Ian Zwicker 23,233,428 344,129 6,022,530
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/0001213900-22-078840-index.htm
- Shareholder Votes
  Emmaus Life Sciences, Inc. shareholders approved To ratify the appointment of Baker Tilly US, LLP as independent registered public accounting firm at the 2022-12-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2022-12-08
  source text: Proposal 3: Votes For Votes Against Votes Withheld Broker Non-Votes To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 29,515,739 50,244 34,104 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/0001213900-22-078840-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.